Cargando…
Ozanezumab Dose Selection for Amyotrophic Lateral Sclerosis by Pharmacokinetic-Pharmacodynamic Modelling of Immunohistochemistry Data from Patient Muscle Biopsies
Amyotrophic Lateral Sclerosis (ALS) is a rare and fatal neurodegenerative disease with a high unmet medical need. In this context, a potential therapy should be brought to patients in the most expeditious way and early exploration of pharmacology is highly beneficial. Ozanezumab, a humanised IgG mon...
Autores principales: | Berges, Alienor, Bullman, Jonathan, Bates, Stewart, Krull, David, Williams, Nicola, Chen, Chao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4338135/ https://www.ncbi.nlm.nih.gov/pubmed/25706882 http://dx.doi.org/10.1371/journal.pone.0117355 |
Ejemplares similares
-
Safety, Pharmacokinetic, and Functional Effects of the Nogo-A Monoclonal Antibody in Amyotrophic Lateral Sclerosis: A Randomized, First-In-Human Clinical Trial
por: Meininger, Vincent, et al.
Publicado: (2014) -
Ibudilast (MN-166) in amyotrophic lateral sclerosis- an open label, safety and pharmacodynamic trial
por: Babu, Suma, et al.
Publicado: (2021) -
Amyotrophic lateral sclerosis
por: Wijesekera, Lokesh C, et al.
Publicado: (2009) -
Liquid biopsy: a new source of candidate biomarkers in amyotrophic lateral sclerosis
por: Mendioroz, Maite, et al.
Publicado: (2018) -
Amyotrophic lateral sclerosis and neuroregeneration
Publicado: (2012)